• 1. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 2. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248
• 3. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 4. Excitation energies from ground-state density-functionals by means of generator coordinates
  A. B. F. da Silva,K. Capelle Phys. Chem. Chem. Phys., 2009,11, 4564-4569
• 5. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzenesulfonamides

Recent Advances in the Study of N,N-Dipropyl 3-bromo-5-trifluoromethylbenzenesulfonamide (CAS: 957062-78-1)

N,N-Dipropyl 3-bromo-5-trifluoromethylbenzenesulfonamide (CAS: 957062-78-1) is a sulfonamide derivative that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential pharmacological applications. Recent studies have focused on its synthesis, structural characterization, and biological activities, particularly in the context of enzyme inhibition and drug discovery. This research brief aims to summarize the latest findings related to this compound, providing insights into its molecular mechanisms and therapeutic potential.

The synthesis of N,N-Dipropyl 3-bromo-5-trifluoromethylbenzenesulfonamide involves a multi-step process, starting with the bromination and trifluoromethylation of benzenesulfonyl chloride, followed by the introduction of dipropylamine groups. Recent advancements in synthetic methodologies have improved the yield and purity of this compound, making it more accessible for further biological testing. High-performance liquid chromatography (HPLC) and nuclear magnetic resonance (NMR) spectroscopy are commonly employed to confirm the structural integrity of the synthesized product.

One of the key areas of research for this compound is its role as an enzyme inhibitor. Preliminary studies have demonstrated its efficacy in inhibiting certain sulfotransferases and carbonic anhydrases, which are implicated in various disease pathways. For instance, its inhibitory activity against carbonic anhydrase IX (CA IX), a marker for hypoxic tumors, suggests potential applications in cancer therapy. Molecular docking studies have revealed that the bromo and trifluoromethyl groups play a critical role in binding to the active site of these enzymes, thereby enhancing inhibitory potency.

In addition to its enzyme inhibitory properties, N,N-Dipropyl 3-bromo-5-trifluoromethylbenzenesulfonamide has also been investigated for its antimicrobial activity. Recent in vitro studies have shown that this compound exhibits moderate to strong activity against a range of Gram-positive and Gram-negative bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and Escherichia coli. The presence of the trifluoromethyl group is believed to contribute to its antimicrobial efficacy by enhancing membrane permeability and disrupting bacterial cell wall synthesis.

Despite these promising findings, challenges remain in the development of N,N-Dipropyl 3-bromo-5-trifluoromethylbenzenesulfonamide as a therapeutic agent. Issues such as bioavailability, metabolic stability, and potential toxicity need to be addressed through further preclinical studies. Recent efforts have focused on structural modifications to optimize its pharmacokinetic properties while retaining its biological activity. For example, the introduction of hydrophilic moieties has been explored to improve solubility and reduce off-target effects.

In conclusion, N,N-Dipropyl 3-bromo-5-trifluoromethylbenzenesulfonamide (CAS: 957062-78-1) represents a promising scaffold for the development of novel enzyme inhibitors and antimicrobial agents. Ongoing research is expected to shed more light on its mechanistic pathways and therapeutic potential, paving the way for future clinical applications. The integration of computational modeling, synthetic chemistry, and biological testing will be crucial in advancing our understanding of this compound and its derivatives.

• 951884-67-6(3-Bromo-N-propyl-5-(trifluoromethyl)benzenesulfonamide)
• 951884-69-8(1-(3-Bromo-5-trifluoromethylphenylsulfonyl)piperidine)
• 951884-65-4(N,N-Dimethyl 3-bromo-5-trifluoromethylbenzenesulfonamide)
• 951884-63-2(3-Bromo-N-hexyl-5-(trifluoromethyl)benzenesulfonamide)
• 951884-61-0(N-Cyclopropyl 3-bromo-5-trifluoromethylbenzenesulfonamide)
• 1020252-96-3(1-(3-Bromo-5-methylphenylsulfonyl)pyrrolidine)
• 1020252-83-8(N-Butyl 3-bromo-5-(trifluoromethyl)benzenesulfonamide)
• 1020253-03-5(N,N-Diethyl 4-bromo-3-trifluoromethylbenzenesulfonamide)
• 1065074-37-4(1-(4-Bromo-3-trifluoromethylphenylsulfonyl)piperidine)
• 1020253-00-2(N-Propyl 4-Bromo-3-trifluoromethylbenzenesulfonamide)